Feb. 26th FDA Advisory Council (VRBPAC) Meeting

The FDA Vaccines and Related Biological Products Advisory Committee met on February 26th to consider the Emergency Use Authorization of the Johnson & Johnson (Janssen Biotech) COVID-19 vaccine.

• Meeting information
• Meeting video
• FDA Briefing Document – Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

Presentation #1

The Vaccine Considerations Project’s founder, Jared Krupnick, provided an oral presentation entitled “Preventing Health Inequities” at the FDA Vaccines and Related Biological Products Advisory Committee meeting on February 26th.

This was Jared’s second time presenting to the VRBPAC, having also presented when the Committee considered the Pfizer vaccine on December 10th.

• Submitted oral presentation application
• Submitted written comments
• Presentation slides
• Presentation video

Dec. 17th FDA Advisory Council (VRBPAC) Meeting

Our Senior Medical Advisor, Dr. David Berger, again, provided an oral presentation at the FDA Vaccines and Related Biological Products Advisory Committee meeting at on December 17th – see the video.

Dec. 10th FDA Advisory Council (VRBPAC) Meeting

Both Jared Krupnick, the Founder of the Vaccine Considerations Project, as well as Board Certified Pediatrician, and the project’s Senior Medical Advisor, Dr. David Berger, were pleased to provide separate oral presentations (Jared’s presentation) (Dr. Berger’s presentation) to the FDA Vaccines and Related Biological Products Advisory Committee meeting on December 10th.

• Oral Presentation Request Package
• Dec. 10th Meeting Information
• Processed Transcript
  (of Oct. 22nd VRBPAC meeting)
• Matrix of Concerns
  (of Oct. 22nd VRBPAC meeting)
• Oct. 22nd VRBPAC meeting video

Leading the 6pm News in Miami / Ft. Lauderdale

See the very supportive news coverage we received of our presentations to the FDA Advisory Committee December 10th.

Vision

We’re working to make sure that all health and safety concerns are given due consideration.

We’re creating a repository of information for everyone contemplating getting a vaccine, and for those advising them, that comprehensively addresses health concerns and considerations.

Public Trust is Necessary

In order to eliminate COVID-19, a large percentage of people need to develop immunity.

Significant vaccine hesitancy has been well documented, and reinforced by recent news.

Widespread concerns must be adequately addressed in order to ensure sufficient buy-in by:

• public health experts
• medical professionals
• the public

Additional Considerations

There may be unforeseen adverse reactions for the COVID vaccines that may emerge in people who have:

• hyperinflammatory conditions
• cancers
• people with poor health or nutrition
• past exposure/immunity to the COVID virus

Organizing Collective Concerns

The Vaccine Considerations Project is consolidating, organizing, and amplifying collective COVID-19 vaccine health and safety concerns of:

• the medical community
• epidemiologists
• public health experts
• the community at large

Collective Action Required

We’re urging all concerned stakeholders to collectively contribute to, and share, a comprehensive repository of information that addresses health and safety concerns for the COVID vaccines.

It’s imperative that we urgently work together to ensure that any approved vaccine is safe.